Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304761 | 0.81 | TSHR (0.52) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL13929133 | 0.80 | TSHR (0.50) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL19415612 | 0.79 | TSHR (0.45) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL5423335 | 0.79 | TSHR (0.48) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL19415683 | 0.78 | TSHR (0.44) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL599239 | 0.77 | TSHR (0.47) | TSHRTACR1IDO1LMNAMMP2 | |
| SCHEMBL213520 | 0.76 | TSHR (0.45) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL9274987 | 0.76 | TSHR (0.45) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL9565489 | 0.76 | TSHR (0.45) | TSHRTACR1CA1CA2CA7 | |
| SCHEMBL9565491 | 0.76 | TSHR (0.45) | TSHRTACR1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| CN-107614501-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| WO-2016184313-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1732918-B1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1732918-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092881-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | TSHR 1264/4885TACR1 2269/4885MEN1 1349/4885 |
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F9, F2, F12 | TSHR 1530/4885TACR1 1376/4885MEN1 2213/4885 |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | TSHR 3261/4885TACR1 2743/4885MEN1 3758/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | TSHR 3261/4885TACR1 2743/4885MEN1 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.